Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

April 22, 2021 updated by: Irene Ghobrial, MD, Dana-Farber Cancer Institute

Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia

The purpose of this research study is to test the safety of the combination of everolimus, rituximab and bortezomib. Everolimus is a drug that works by preventing cells in your body from growing and dividing. Information from basic and other clinical research suggests that everolimus may also inhibit tumor growth in people with relapsed or refractory lymphoma. The FDA has approved everolimus for the treatment of multiple myeloma, a cancer that is closely related to Waldenstrom's Macroglobulinemia. Rituximab is approved by the FDA for the treatment of non-Hodgkin's lymphoma, which included Waldenstrom's Macroglobulinemia.

Funding Source - FDA OOPD

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Study Design

This is a phase I/II study. The phase I portion of the study will determine the maximum tolerated dose of everolimus, rituximab, and bortezomib combination, while the phase II portion will evaluate the depth of responses to the everolimus, rituximab, and bortezomib combination. If patients show response, they will continue on therapy for a total of 6 cycles, and then go on maintenance therapy with everolimus alone until progression. Patients on maintenance will be monitored every 3 months for response. Because of the potential of an IgM flare after rituximab, patients who show an increase in IgM after rituximab in the first 3 months will not be deemed as having progressive disease unless they show evidence of clinical progression and not just an increase of IgM levels. If biochemical progression is confirmed by m-spike, but the participant is clinically benefitting from therapy, the participant may continue on treatment for a few additional points of assessment and re-discuss benefit of therapy. Additionally, if the participant progressed because the treatment was held, participant may remain on study at the discretion of the overall Principal Investigator. Relapse from CR is defined by the reappearance of monoclonal IgM protein and/or recurrence of bone marrow involvement, lymphadenopathy/splenomegaly or symptoms attributable to active disease (Owen et al., 2012). Progression from PR is defined by ≥ 25% increase in IgM level from lowest recorded value and confirmed by a repeat assessment. The development of new signs and symptoms of disease, including Bing Neel syndrome and histological transformation, is also considered as evidence of disease progression. An absolute increase of at least 5 g/l is required to define progression when the IgM level is the only applicable criterion (Owen et al., 2012).

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Dana-Farber Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years of age or older
  • Patients must have received prior therapies for their WM and have relapsed or refractory WM requiring therapy. Any number of prior therapies is acceptable. Patients must not have been refractory to rituximab. The last rituximab must be at least 3 months prior to the start of treatment. Prior treatment with bortezomib and/or everolimus is permitted.
  • Measurable monoclonal IgM protein in the serum OR measurable quantitative immunoglobulin M (serum IgM).
  • Lymphoplasmacytic cells in the bone marrow during any previous bone marrow biopsy.
  • CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed prior to enrollment.
  • ECOG Performance Status 0, 1 or 2
  • Laboratory values as outlined in the protocol
  • Capable of swallowing intact study medication tablets
  • Life expectancy of 12 weeks or greater

Exclusion Criteria:

  • Uncontrolled infection
  • Other active malignancies
  • Cytotoxic chemotherapy 3 weeks or less, or biologic or targeted novel therapy 2 weeks or less, or corticosteroids 2 weeks or less, or radiation therapy 2 weeks or less, or any ancillary treatment considered investigation 2 weeks or less, prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than WM.
  • Pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception throughout the trial and for 8 weeks after the last dose of study treatment.
  • Known to be HIV positive, or Hepatitis B positive. If the status of HIV is not known and patients are not at risk, then patients will not be specifically tested for HIV. Patients will be tested for Hepatitis B at time of screening. If patients are not considered high risk and have been vaccinated at an earlier date, results of the test are not required at the time of registration. For patients that are high risk, results must be obtained prior to registration.
  • Patient has Grade 2 or higher peripheral neuropathy within 14 days of enrollment
  • Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection fo basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  • Severely impaired lung function
  • Uncontrolled diabetes
  • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
  • Impairment of gastrointestinal function or gastrointestinal disease
  • Patients with active, bleeding diathesis
  • Myocardial infarction within 6 months prior to enrollment or had NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  • Hypersensitivity to everolimus or other rapamycins or to is excipients
  • Patients who may need or are receiving live vaccines for immunization
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase I Stage A Level 1

Combination of everolimus & rituximab for 6 cycles:

Everolimus 5 mg: Taken orally on a daily basis x 28 days

Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only

(1 cycle = 28 days)

Maintenance:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

(1 cycle = 28 days)

Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons.
Drug: Rituximab
Other Names:
  • Rituxan
Drug: Everolimus
Other Names:
  • RAD001
Experimental: Phase I Stage A Level 2

Combination of everolimus & rituximab for 6 cycles:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only

(1 cycle = 28 days)

Maintenance:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

(1 cycle = 28 days)

Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons.
Drug: Rituximab
Other Names:
  • Rituxan
Drug: Everolimus
Other Names:
  • RAD001
Experimental: Phase I Stage B Level 1

Combination of everolimus & rituximab with bortezomib for 6 cycles:

Everolimus 5 mg: Taken orally on a daily basis x 28 days

Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only

Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)

Maintenance:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

(1 cycle = 28 days)

Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons.
Drug: Rituximab
Other Names:
  • Rituxan
Drug: Everolimus
Other Names:
  • RAD001
Drug: Bortezomib
Other Names:
  • Velcade
  • PS-341
Experimental: Phase I Stage B Level 2

Combination of everolimus & rituximab with bortezomib for 6 cycles:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only

Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle

(1 cycle = 28 days)

Maintenance:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

(1 cycle = 28 days)

Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons.
Drug: Rituximab
Other Names:
  • Rituxan
Drug: Everolimus
Other Names:
  • RAD001
Drug: Bortezomib
Other Names:
  • Velcade
  • PS-341
Experimental: Phase I Dose Expansion

Combination of everolimus & rituximab with bortezomib for 6 cycles:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only

Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle

(1 cycle = 28 days)

Maintenance:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

(1 cycle = 28 days)

Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons.
Drug: Rituximab
Other Names:
  • Rituxan
Drug: Everolimus
Other Names:
  • RAD001
Drug: Bortezomib
Other Names:
  • Velcade
  • PS-341
Experimental: Phase II

Combination of everolimus & rituximab with bortezomib for 6 cycles:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only

Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle

Maintenance:

Everolimus 10 mg: Taken orally on a daily basis x 28 days

(1 cycle = 28 days)

Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons.
Drug: Rituximab
Other Names:
  • Rituxan
Drug: Everolimus
Other Names:
  • RAD001
Drug: Bortezomib
Other Names:
  • Velcade
  • PS-341

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Everolimus Maximum Tolerated Dose (MTD) Stage A [Phase I]
Time Frame: Assessed within the first cycle (28 days) of the study.
The MTD of Everolimus/Rituximab combination is determined by the number of patients who have dose limiting toxicity (DLT). See DLT primary outcome measure for definition. MTD is defined as the highest dose where <1/3 participants experience a DLT. If no DLT's are observed on Level 1, 3 subjects will be enrolled in the Level 2. If >1/3 subjects in a cohort have DLT, that dose will not be considered safe, with no escalation (MTD exceeded). If 1/3 subjects experience DLT, the cohort will be expanded to 6 subjects. If <2 subjects with a DLT among the expanded cohort of 6 evaluable subjects a cohort of 3 subjects will be enrolled in the next higher dose level. If 2 or more subjects with a DLT among the expanded cohort of 6 subjects, that dose level will not be considered safe, no escalation (MTD exceeded). If no DLT's are observed, then the MTD is not reached. The MTD was not reached with 0/3 participants experiencing a DLT in the highest dose level. Higher doses were not planned/tested.
Assessed within the first cycle (28 days) of the study.
Everolimus Maximum Tolerated Dose (MTD) Stage B [Phase I]
Time Frame: Assessed within the first cycle (28 days) of the study.
The MTD of Everolimus/Bortezomib/Rituximab combination is determined by the number of patients who have dose limiting toxicity (DLT). See DLT primary outcome measure for definition. MTD is defined as the highest dose where <1/3 participants experience a DLT. If no DLT's are observed on Level 1, 3 subjects will be enrolled in the Level 2. If >1/3 subjects in a cohort have DLT, that dose will not be considered safe, with no escalation (MTD exceeded). If 1/3 subjects experience DLT, the cohort will be expanded to 6 subjects. If <2 subjects with a DLT among the expanded cohort of 6 evaluable subjects a cohort of 3 subjects will be enrolled in the next higher dose level. If 2 or more subjects with a DLT among the expanded cohort of 6 subjects, that dose level will not be considered safe, no escalation (MTD exceeded).If no DLT's observed, then the MTD is not reached. The MTD was not reached with 0/3 participants experiencing a DLT in the highest level. Higher doses were not planned/tested.
Assessed within the first cycle (28 days) of the study.
Everolimus Dose Limiting Toxicity (DLT) [Phase I]
Time Frame: Assessed within the first cycle (28 days) of the study.

The following qualify as dose limiting toxicities:

  • Grade 3 or greater non-hematologic toxicity, considered by the investigator to be related to study drugs.
  • Grade 4 hematologic toxicity defined as: thrombocytopenia with platelets <10,000 µ/L on more than one occasion despite transfusion support; grade 4 neutropenia occurring for more than 7 days and/or resulting in neutropenic fever with elevated temperature (defined as > 101 degrees F). Lymphopenia, a recognized side effect of bortezomib, is not considered a DLT.
  • Inability to receive Day 1 dose for Cycle 2 due to toxicity
Assessed within the first cycle (28 days) of the study.
Very-good-partial-response-or-better Rate [Phase II]
Time Frame: Up to 6 cycles (Day 168)

Very-good-partial-response-or-better rate is the percentage of participants with complete response (CR) or very good partial response (VGPR) on to the combination of everolimus/bortezomib/rituximab. The combination regimen was received for up to 6 cycles.

CR:

  • Absence of serum monoclonal IgM protein by immunofixation
  • Normal serum IgM level
  • Complete resolution of extramedullary disease, i.e., lymphadenopathy and splenomegaly if present at baseline
  • Morphologically normal bone marrow aspirate and trephine biopsy

VGPR:

  • Monoclonal IgM protein is detectable ≥90% reduction in serum IgM level from baseline*
  • Complete resolution of extramedullary disease, i.e.
Up to 6 cycles (Day 168)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment-Emergent Sensory Neuropathy Rate [Phase I]
Time Frame: Adverse events were assessed each cycle (ever 28 days) for 6 cycles then every 3 months on maintenance. Duration of therapy for the Phase I study up to 41 months.
Percentage of participants experiencing Grade 1 - Grade 3 treatment-emergent peripheral (sensory) neuropathy events based on CTCAEv3 as reported on case report forms for phase I participants.
Adverse events were assessed each cycle (ever 28 days) for 6 cycles then every 3 months on maintenance. Duration of therapy for the Phase I study up to 41 months.
Phase II Overall Response Rate
Time Frame: Up to 6 cycles (Day 168)

Overall response rate is percentage of participants with complete (CR), very good partial (VGPR), partial (PR), or minimal response (MR) as best response during treatment.

CR:

  • No serum monoclonal IgM protein by immunofixation
  • Normal IgM level
  • Complete resolution of extramedullary disease, i.e., lymphadenopathy and splenomegaly if present at baseline
  • Morphologically normal bone marrow aspirate and trephine biopsy

VGPR:

  • Monoclonal IgM protein is detectable ≥90% reduction in IgM level from baseline
  • Complete resolution of extramedullary disease, i.e., lymphadenopathy/splenomegaly if present at baseline
  • No new signs/symptoms of active disease

PR:

  • Monoclonal IgM protein is detectable ≥50% but <90% reduction in IgM level from baseline
  • Reduction in extramedullary disease
  • No new signs/symptoms of active disease

MR:

  • Monoclonal IgM protein is detectable ≥25% but <50% reduction in IgM level from baseline
  • No new signs/symptoms of active disease
Up to 6 cycles (Day 168)
2-year Time-to-progression Probability (TTP) [Phase II]
Time Frame: Patients were assessed for disease every cycle while on treatment (168 days) and every three months while on maintenance therapy. In long-term follow-up, disease was monitored every 3 months. Study cohort median (range) follow-up was 15 (1 - 23) months.
2-year TTP probability is based on Kaplan-Meier methods. TTP is defined as time from enrollment to the date of progressive disease (PD). PD is defined as ≥25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable the disease. Patients without PD and not reporting use of non-protocol therapy prior to PD are censored at date of last objective progression-free disease assessment. Patients reporting use of non-protocol therapy prior to PD are censored at date of last objective progression-free disease assessment date prior to post-discontinuation therapy.
Patients were assessed for disease every cycle while on treatment (168 days) and every three months while on maintenance therapy. In long-term follow-up, disease was monitored every 3 months. Study cohort median (range) follow-up was 15 (1 - 23) months.
2 Year Progression-free-survival [Phase II]
Time Frame: Patients were assessed for disease every cycle while on treatment (168 days) and every three months while on maintenance therapy. In long-term follow-up, disease was monitored every 3 months. Study cohort median (range) follow-up was 15 (1 - 23) months.
2-year progression free survival (PFS) is the probability of participants alive and progression free at 2 years from study entry estimated using Kaplan-Meier methods. PFS is defined as the time from enrollment to progressive disease (PD) or death. PD is defined as ≥25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable the disease. Patients alive without PD and not reporting use of non-protocol therapy prior to PD are censored at date of last objective progression-free disease assessment. Patients reporting use of non-protocol therapy prior to PD are censored at date of last objective progression-free disease assessment date prior to post-discontinuation therapy.
Patients were assessed for disease every cycle while on treatment (168 days) and every three months while on maintenance therapy. In long-term follow-up, disease was monitored every 3 months. Study cohort median (range) follow-up was 15 (1 - 23) months.
Phase II Duration of Response (DoR)
Time Frame: Patients were assessed for disease every cycle while on treatment (168 days) and every three months while on maintenance therapy. In long-term follow-up, disease was monitored every 3 months. Study cohort median (range) follow-up was 15 (1 - 23) months.

The DoR is defined as the elapsed time from date when the measurement criteria are first met for a complete or partial response (whichever status is recorded first) until the date of first observation of objective disease progression. Analysis of DoR will be as follows:

  • For responding patients who die without objective PD (including death from study disease), DoR will be censored at the date of the last objective progression-free disease assessment.
  • For responding patients not known to have died as of the data cut-off date and who do not have objective PD, DoR will be censored at the date of the last objective progression-free disease assessment.
  • For responding patients who receive subsequent systemic anticancer therapy (after discontinuation from the study chemotherapy) prior to objectively determined disease progression, DoR will be censored at the date of the last objective progression-free disease assessment prior to post discontinuation therapy.
Patients were assessed for disease every cycle while on treatment (168 days) and every three months while on maintenance therapy. In long-term follow-up, disease was monitored every 3 months. Study cohort median (range) follow-up was 15 (1 - 23) months.
PTEN Mutation Rate [Phase II]
Time Frame: Samples were collected pre-therapy before the beginning therapy (baseline) and post-therapy after finishing the 6th treatment cycle (168 days).
The PTEN mutation rate is the percentage of patients with PTEN mutation identified in pre-therapy and post-therapy bone marrow samples per established methods.
Samples were collected pre-therapy before the beginning therapy (baseline) and post-therapy after finishing the 6th treatment cycle (168 days).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dana-Farber Cancer Institute

Collaborators

Novartis
Millennium Pharmaceuticals, Inc.

Investigators

  • Principal Investigator: Irene Ghobrial, MD, Dana-Farber Cancer Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2010

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

August 1, 2014

Study Registration Dates

First Submitted

March 16, 2010

First Submitted That Met QC Criteria

May 17, 2010

First Posted (Estimate)

May 18, 2010

Study Record Updates

Last Update Posted (Actual)

April 23, 2021

Last Update Submitted That Met QC Criteria

April 22, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 09-280
  • R01FD003743; X05310 (Other Grant/Funding Number: FDAOOPD; Millennium)
  • R01FD003743 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Waldenstrom's Macroglobulinemia

Clinical Trials on Rituximab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe